MARTINSRIED / MUNICH, Germany, Aug. 29, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences:
Commerzbank Sector Conference 2016
Date: August 30, 2016
Venue: Frankfurt, Germany
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG;
Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR
Goldman Sachs Annual Biotech Symposium
Date: September 9, 2016
Venue: London, UK
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG;
Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR
Morgan Stanley Global Healthcare Conference
Date: September 12-14, 2016
Venue: New York, NY, USA
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG;
Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR
J.P. Morgan London Small/Mid Cap Conference
Date: September 13, 2016
Venue: London, UK
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG
Bank of America Merrill Lynch Global Healthcare Conference 2016
Date: September 15, 2016, 4:10 pm BST (11:10 am EDT, 5:10 pm CEST)
Venue: London, UK
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG;
Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR
Fifth Berenberg and Goldman Sachs Annual German Corporate Conference
Date: September 20, 2016, 4:30 pm CEST (3:30 pm BST, 10:30 am EDT)
Venue: Munich, Germany
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG;
Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG
Baader Investment Conference
Date: September 22, 2016, 8:00 am CEST (7:00 pm BST, 2:00 am EDT)
Venue: Munich, Germany
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG;
Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR
A PDF version of the presentations will be provided at www.morphosys.com.
The link to webcasts will be filed under www.morphosys.com/conference-calls.
About MorphoSys
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com
Conference Announcement (PDF) http://hugin.info/130295/R/2037845/759368.pdf